Academic Writing Sample Answers Practice 10 Test 04

The convergence of biotechnology and information technology is enabling scientists to design cells, microbes and living materials for specific purposes. Such systems might deliver treatment inside the body or help a building repair small cracks, but their capacity to grow and evolve distinguishes them from ordinary machines. I believe innovation should proceed, and sometimes rapidly, but the degree of caution must correspond to the reversibility and reach of each application.

Those favouring caution emphasise that living systems can behave differently outside controlled conditions. An engineered organism released into soil might interact with native species, exchange genetic material or spread farther than expected. Even medical applications confined to an individual could produce delayed immune effects that short trials fail to reveal. There are also questions of accountability: if a living construction material changes over time, responsibility for a later failure may be divided among its designer, manufacturer and building owner. Because some consequences could be difficult to reverse, critics reasonably argue that commercial pressure should not substitute for long-term observation.

Conversely, excessive restraint has costs of its own. Engineered tissues could improve the testing of medicines and potentially reduce dependence on scarce donor organs, while programmable biological systems may allow treatment to be delivered more precisely. In construction, materials capable of repairing minor damage could extend the life of infrastructure and reduce demand for resource-intensive replacement. These benefits are particularly valuable when societies face ageing populations, housing needs and environmental pressure. Innovation also becomes safer through practice: carefully conducted trials generate evidence that theoretical discussion alone cannot provide.

In my view, regulation should distinguish contained, reversible work from open and potentially permanent interventions. Laboratory research on a living material that cannot survive outside a controlled facility should face proportionate oversight rather than years of delay. A self-replicating organism intended for environmental release, by contrast, should require independent ecological assessment, staged trials and long-term monitoring. Designers could incorporate biological limits that reduce survival beyond the intended setting, although such safeguards should themselves be tested rather than assumed effective. Public reporting and clear liability rules would further ensure that developers retain responsibility after approval.

Caution and speed are therefore not genuine opposites. A risk-based system can accelerate applications with limited consequences while demanding stronger evidence for those capable of spreading or evolving. This approach allows society to obtain valuable medical and material innovations without treating uncertainty as either a reason for paralysis or an excuse for recklessness.

New combinations of biotechnology and information technology can produce living systems that perform practical tasks. These developments may improve medical treatment and create more sustainable building materials, but they may also have effects that are difficult to predict. In my opinion, innovation should be encouraged under risk-based regulation, with much stricter controls on technologies that can reproduce or spread beyond a controlled setting.

Supporters of a cautious approach argue that biological products are not completely predictable. An engineered microbe may behave safely in a laboratory but interact differently with other organisms if it enters the wider environment. Its genetic features could change or move into another population, creating consequences that are hard to reverse. Medical products also require careful testing because a living treatment might cause an unexpected immune response or continue functioning longer than intended. In construction, uncertainty about how living materials age could create safety and legal problems many years after a building is completed.

However, delaying all development would prevent society from gaining important benefits. Engineered cells may help researchers test drugs more accurately or deliver treatment to a particular part of the body. Living materials used in concrete or other building products might repair small amounts of damage, extending the useful life of structures and reducing waste. Faster innovation can also attract investment and skilled researchers, leading to further improvements in safety and performance. Without practical trials, governments cannot collect the evidence needed to understand either the value or the risks of these technologies.

I therefore favour different rules for different levels of danger. Research conducted in secure laboratories should usually be allowed to progress after standard safety checks. Human treatments require staged clinical testing and continued monitoring after approval. Products designed for release into nature should face the strongest assessment because they may cross borders and be impossible to recall. Developers should publish safety information, prepare plans for failures and remain legally responsible for harm caused by their products.

In conclusion, uncertainty justifies caution but not a general slowdown in biotechnology. Society should permit controlled experimentation and useful applications while applying tougher standards whenever a living system could spread, evolve or create irreversible effects.

Biotechnology and information technology are now being combined to create useful living systems and materials. These products may offer major benefits in medicine and construction, but their future effects are not always clear. I believe development should continue, although governments should apply stronger safety rules to higher-risk uses.

People who support caution are concerned that living systems can grow, change and interact with the environment. For example, a modified microorganism may work as planned inside a laboratory but behave differently if it escapes into soil or water. It could affect other species or spread beyond the area where it was originally needed. Medical uses also involve risks because an engineered cell might cause an unexpected reaction in a patient. Similarly, a living building material could become weaker or change after many years. These possibilities mean that testing must not be rushed simply because a product could be profitable.

On the other hand, faster innovation may produce valuable social benefits. Engineered biological materials could help scientists study diseases and test possible treatments. Some living systems might deliver medicine more accurately, reducing damage to healthy parts of the body. In construction, a material that repairs small cracks could make buildings and bridges last longer and reduce the need for replacement materials. Allowing researchers to conduct practical trials also provides real evidence about how these inventions work. If every project is delayed because of uncertainty, useful products may never reach the people who need them.

In my view, the correct level of control depends on the possible harm. Experiments carried out in secure laboratories should be permitted when researchers follow clear safety procedures. Medical products should pass through several testing stages and continue to be monitored after approval. Governments should be much more careful about organisms intended for release into the natural environment, since recalling them may be impossible. Companies must explain known risks and remain responsible if their products cause damage.

In conclusion, innovation and caution can be combined. Governments should support research and controlled trials, while requiring stronger evidence for technologies that may spread or have permanent effects. This would allow society to gain benefits without ignoring serious long-term risks.